News coverage about Cardiovascular Systems (NASDAQ:CSII) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cardiovascular Systems earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 47.811016518728 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events … – Business Wire (press release) (businesswire.com)
- Cardiovascular Systems, Inc. (CSII) is at $30.59 per share and Aclaris Therapeutics, Inc. (ACRS) is listed at $26.97 – Stocks Gallery (stocksgallery.com)
- LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360 … (businesswire.com)
- A new sub-analysis from the landmark LIBERTY 360° study, sponsored by Cardiovascular Systems, Inc. (thestreet.com)
- LIBERTY 360° Study 12-Month Data Demonstrate Lasting Benefits Following Endovascular Intervention in Patients with Critical Limb Ischemia (CLI) (finance.yahoo.com)
Shares of Cardiovascular Systems (NASDAQ CSII) opened at 30.57 on Friday. The firm’s market cap is $1.00 billion. The stock has a 50 day moving average price of $31.68 and a 200-day moving average price of $29.58. Cardiovascular Systems has a 1-year low of $21.29 and a 1-year high of $33.11.
Cardiovascular Systems (NASDAQ:CSII) last posted its earnings results on Wednesday, August 2nd. The medical device company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.07. Cardiovascular Systems had a positive return on equity of 0.89% and a negative net margin of 0.87%. The company had revenue of $52.90 million for the quarter, compared to analyst estimates of $51.98 million. During the same period last year, the company earned ($0.15) earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year. On average, equities research analysts expect that Cardiovascular Systems will post $0.04 earnings per share for the current fiscal year.
Several equities research analysts have commented on CSII shares. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Cardiovascular Systems in a research note on Tuesday, April 18th. TheStreet upgraded Cardiovascular Systems from a “d” rating to a “c-” rating in a research note on Thursday, May 4th. BidaskClub upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating in a research note on Friday, June 9th. Bank of America Corporation lowered Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a research note on Wednesday, June 21st. Finally, Zacks Investment Research lowered Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Three analysts have rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. Cardiovascular Systems currently has a consensus rating of “Hold” and a consensus target price of $33.83.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://transcriptdaily.com/2017/08/13/cardiovascular-systems-csii-given-news-sentiment-rating-of-0-12.html.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.